New Hope on the Horizon as Bundibugyo Ebola Threat Persists in DRC
There s no treatment designed – More than 50 days have passed since the Ebola outbreak was officially declared in the Democratic Republic of Congo and Uganda, yet the crisis continues to unfold with alarming speed. Medical professionals working in the field are racing against time to treat critically ill patients, but their efforts are being hindered by the absence of targeted therapies for the specific strain currently in circulation. This virus, known as Bundibugyo, has proven to be a formidable challenge, as it differs from the Zaire strain that has historically dominated previous outbreaks.
The Looming Gap in Treatment Options
While the Zaire strain has been the focus of extensive research, Bundibugyo remains relatively understudied. According to Amanda Rojek, a physician scientist at the University of Oxford, the lack of specialized treatments is a critical obstacle. “We urgently need therapies that can address the unique characteristics of Bundibugyo,” she explains, emphasizing that this variant presents a distinct set of complications compared to its more well-known counterpart. The absence of proven drugs not only limits immediate interventions but also leaves exposed individuals vulnerable to infection without effective preventive measures.
“One of the key lessons from recent outbreaks is that research needs to happen alongside the response, not after it,” Rojek adds, highlighting the importance of simultaneous scientific exploration and on-the-ground action. Her insights underscore the necessity of adapting medical strategies to match the evolving nature of the epidemic.
Rapid Response and Repurposed Medications
The World Health Organization’s recent announcement marks a pivotal shift in the battle against the disease. Last Thursday, it confirmed the initiation of clinical trials to evaluate two promising drugs against Bundibugyo. This accelerated approach reflects a broader strategy of leveraging existing treatments rather than starting from scratch. As Salim Abdool Karim, director of the Centre for the AIDS Programme of Research in South Africa, notes, “Developing new therapies from the ground up can take years, so repurposing available medications is a pragmatic solution.” This method allows researchers to build on prior knowledge, potentially expediting results in a high-stakes scenario.
The trials will test both remdesivir, an antiviral initially developed for respiratory illnesses like COVID-19, and MBP-134, a monoclonal antibody treatment derived from survivors of the 2014-2016 West African outbreak. These drugs, though not specifically designed for Bundibugyo, offer a starting point for exploration. Remdesivir, which gained global attention during the pandemic, was previously evaluated against the Zaire strain but showed limited efficacy. In contrast, MBP-134, composed of two antibodies isolated from survivors, has generated preliminary data suggesting it may combat the Bundibugyo variant effectively.
The Biomedical Advanced Research and Development Authority (BARDA), a U.S. government agency under the Department of Health and Human Services, has been instrumental in funding the development of MBP-134. Vasee Moorthy, WHO’s research and development lead for the outbreak, states that BARDA technically owns the drug doses, which have been donated for use in the trial. This partnership highlights the international collaboration essential to addressing the crisis, as the pandemic has demonstrated the power of cross-border scientific cooperation.
Trials in Motion: A Multinational Effort
With the trials now in progress, the focus shifts to how these drugs might perform against the current strain. Each drug will be assessed individually and in combination with the standard supportive care, which involves fluid replacement and pain management. The initial phase includes only one clinic in the DRC, but expansion is already in the works, according to Moorthy. “The trial’s scope will grow in the coming weeks,” he says, as the goal is to gather sufficient data to determine their viability.
Moorthy acknowledges that the timeline for results is uncertain. “The duration of the trial depends on multiple factors, including the number of patients enrolled and the consistency of outcomes,” he explains. He estimates that the process could take several months, possibly extending into the next year. “We might need over 1,000 participants to confirm whether these treatments make a significant difference,” he says, noting that rapid success could shorten the timeline if the drugs demonstrate extraordinary efficacy.
Looking Beyond Treatments: The Need for Prevention
While the trials offer hope for treatment, health officials stress that prevention is equally vital. Yazdan Yazdanpanah, an infectious disease expert at ANRS Emerging Infectious Diseases in France, emphasizes that controlling the epidemic requires more than just managing symptoms. “We need to stop the spread before people get infected,” he says. A vaccine, he argues, would be the most effective tool, though one does not yet exist. “It’ll be months before we can test vaccines in large-scale trials,” he adds, underscoring the urgency of finding alternative strategies to curb transmission.
The current outbreak has already claimed over 500 lives and infected more than 1,560 individuals, with some experts warning it could surpass all previous records. This has prompted a reevaluation of global health priorities, with the focus now on rapid intervention. The trials, which combine existing therapies with new insights, represent a critical step toward combating the strain. However, the success of these efforts will depend on the speed of data collection and the adaptability of medical responses.
As the situation evolves, the collaboration between WHO, Africa CDC, universities, and nonprofits continues to be a cornerstone of the strategy. The trials not only test the effectiveness of drugs but also serve as a model for how scientific innovation can be applied to emerging threats. By integrating research with real-world application, health workers aim to close the gap in treatment options and provide a lifeline for patients in the DRC. This approach, as Rojek highlights, ensures that the response remains dynamic and responsive to the challenges posed by the Bundibugyo strain.
Subscribing to NPR’s Global Health newsletter provides access to ongoing updates about such critical developments. As the trials progress, the international community watches closely, hoping for breakthroughs that could reshape the fight against Ebola and set a precedent for future outbreaks. The path forward remains uncertain, but the collective effort to develop and deploy these tools offers a beacon of hope in an otherwise daunting situation.
